Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2026-02-21 @ 1:33 AM
Study NCT ID:
NCT01909934
Status:
COMPLETED
Last Update Posted:
2025-09-19
First Post:
2013-07-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Sponsor:
Takeda
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lymphoma | View |
| None | Anaplastic Large-cell | View |
| None | Relapsed | View |
| None | Refractory | View |
| None | Antigens, CD30 | View |
| None | Antibody-Drug Conjugate | View |
| None | Antibodies, Monoclonal | View |
| None | Lymphoma, Non-Hodgkin | View |
| None | Lymphoma, Large-Cell, Anaplastic | View |
| None | monomethyl auristatin E | View |
| None | Drug Therapy | View |
| None | Immunotherapy | View |
| None | Hematologic Diseases | View |